major histocompatibility complex, class II, DR beta 9 (pseudogene)Genealiases: D6S206 · D6S206E · HLA-DR1BL · HLA-DRB1L
Q-omics provides the consensus-scored HLA-DRB9 profile across patient tissues and cancer cell-line models. HLA-DRB9 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HLA-DRB9 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, HLA-DRB9 RNA expression shows 11,843 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, KIRC, and THYM as cancer lineages where HLA-DRB9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLA-DRB9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLA-DRB9 survival associations across molecular data types. HLA-DRB9 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLA-DRB9 RNA expression–survival associations across cancer types. High HLA-DRB9 expression shows unfavorable associations in LUSC, LAML, LGG, UVM and MESO, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HLA-DRB9 RNA expression.
This table summarizes HLA-DRB9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HLA-DRB9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLA-DRB9 shows lower tumor expression in LUAD, LUSC, KICH and UCEC and higher tumor expression in KIRC and COAD. The KIRC box plot shows higher HLA-DRB9 RNA expression in tumor versus normal tissue (log2 FC = +0.926, t-test p < 0.001).
This table shows molecular features associated with HLA-DRB9 in patient tissues and cancer cell lines. In patient samples, HLA-DRB9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
